NCT05959044 is a Phase 2 clinical trial of Folic Acid Tablet in Parkinson Disease, sponsored by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.

Who is sponsoring NCT05959044?

NCT05959044 is sponsored by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.

What drugs are being tested in NCT05959044?

Interventions in NCT05959044: Folic Acid Tablet, Placebo.

What condition does NCT05959044 study?

NCT05959044 studies Parkinson Disease.

Is NCT05959044 still recruiting?

NCT05959044 is currently status unknown. Last updated 26 September 2023.

Last reviewed 2023-09-26 · How we verify

NCT05959044

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Folic Acid in Levodopa Treated Parkinson's Disease Patients

Status unknown Phase 2 Last updated 26 September 2023

What this trial tests

Phase 2 trial testing Folic Acid Tablet in Parkinson Disease in 60 participants. Status unknown.

Timeline

16 April 2023

Primary endpoint
16 July 2024

16 July 2024

Quick facts

Lead sponsor	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	60
Start date	16 April 2023
Primary completion	16 July 2024
Estimated completion	16 July 2024
Sites	1 location across Bangladesh

Drugs / interventions tested

Folic Acid Tablet
Placebo

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Who can join

18 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective single center, randomized, double-blind, 2 arm placebo-controlled study in subjects with Parkinson's disease receiving levodopa .The patients will be randomized to receive tablet Folic Acid 10 mg per day or placebo for 8 weeks. The safety and efficacy outcome measures will be assessed at baseline and 8 weeks.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Nanotherapeutic Interventions for Parkinson's Disease: Modulating Pathogenic Mechanisms and Overcoming Therapeutic Obstacles.
Yin X, Wang C, Lin W, Huang S, et al · · 2026 · PMID 41907367 · DOI 10.2147/ijn.s570452

Verify or expand the search:

Other trials of Folic Acid Tablet

Trials testing the same drug.

NCT05500690 — Understanding Effects of Folic Acid on the Methylosome and Transcriptome of Women With Spina Bifida Affected Pregnancies · NA · completed
NCT04024254 — A Study of Serum Folate Levels in Patients Treated With Olaparib · Phase 4 · completed
NCT03823248 — Jianpi Huoxue Recipe in Treating Gastric Premalignant Lesion · Phase 1, PHASE2 · unknown

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh trials

Trials by the same sponsor.

NCT07507045 — Education-Based Oral Health Promotion Intervention During Pregnancy: Implementation Protocol in Bangladesh · NA · not yet recruiting
NCT07537634 — Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication · Phase 4 · not yet recruiting
NCT07161336 — Role of Methotrexate in Ultrasound Proven Synovitis in Primary Knee OA · Phase 2 · recruiting
NCT06960694 — Effect of L-carnitine on Disease Activity in Patients With Mild to Moderate Knee Osteoarthritis · Phase 2 · completed
NCT07123922 — Effect of Silymarin as Add on Therapy on Oxidative Stress, Pulmonary Function and Quality of Life in Stable COPD Patient · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05959044 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Last refreshed: 26 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05959044.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing